Dr. Sarah Wakeman and Wake Up FDA spokesperson Ryan Hampton recently published an op-ed in The Tennessean.

While stigma has been a long-recognized barrier to expanding access to MAT, recently, surprising new adversaries have surfaced — the largest buprenorphine manufacturer and the government agency chartered with protecting patients: the FDA.

Read the full article here.